The primary role of a non-executive director is to maintain objectivity and independence, providing an external perspective that enhances the board’s decision-making process. So how can Pete possibly maintain that independence and objectivity when he’s the Managing Director of a company set to profit from a formal contract with AGY? And not just one contract, but two—especially now that Lycopodium has taken a 60% stake in Saxum.
It’s clear as day this doesn’t pass the pub test. I think you need to have a read of the AGY charter:
AGY Price at posting:
3.7¢ Sentiment: None Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)